Skip to main content

Table 3 IPTW adjusted Cox regressions comparing SGLT-2i to GLP-1RA after stratification according to pre-existing CVD, pre-existing cardiorenal disease, pre-existing HF, and pre-existing albuminuria

From: Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Outcome

 

Total mortality

MACE

Fatal CVD

Myocardial infarction

Stroke

HF

Renal composite

PAD

Pre-index CVD

HR (95% CI)

0.65 (0.40–1.05)

0.9 (0.74–1.10)

1.95 (0.47–8.12)

0.94 (0.57–1.54)

1.03 (0.54–1.98)

0.79 (0.54–1.16)

1.05 (0.89–1.22)

2.56 (1.09–6.01)

P-value

0.080

0.303

0.356

0.792

0.927

0.238

0.584

0.030

Free from pre-index CVD

HR (95% CI)

0.86 (0.64–1.15)

1.27 (1.00-1.62)

0.69 (0.27–1.77)

0.94 (0.62–1.43)

1.74 (1.11–2.68)

0.84 (0.60–1.17)

0.97 (0.90–1.04)

1.37 (0.77–2.46)

P-value

0.300

0.053

0.447

0.768

0.014

0.295

0.399

0.288

Pre-index cardiorenal disease

HR (95% CI)

0.71 (0.49–1.02)

0.93 (0.77–1.12)

1.28 (0.44–3.70)

1.01 (0.63–1.63)

1.07 (0.65–1.75)

0.8 (0.57–1.11)

0.93 (0.85–1.01)

2.03 (1.05–3.91)

P-value

0.067

0.422

0.648

0.968

0.792

0.176

0.090

0.034

Free from pre-index cardiorenal disease

HR (95% CI)

0.91 (0.65–1.29)

1.30 (0.99–1.71)

0.68 (0.22–2.14)

0.88 (0.57–1.37)

2.08 (1.21–3.58)

0.81 (0.55–1.19)

1.01 (0.91–1.12)

1.44 (0.71–2.91)

P-value

0.604

0.056

0.513

0.577

0.008

0.281

0.828

0.316

Pre-index HF

HR (95 % CI)

0.80 (0.46–1.39)

0.99 (0.65–1.49)

1.88 (0.36–9.87)

0.86 (0.29–2.56)

1.74 (0.40–7.45)

0.92 (0.64–1.31)

0.97 (0.73–1.29)

16.47 (1.99-136.06)

P-value

0.426

0.954

0.458

0.793

0.459

0.636

0.821

0.009

Free from pre-index HF

HR (95% CI)

0.81 (0.61–1.07)

1.04 (0.89–1.23)

0.91 (0.39–2.10)

0.95 (0.68–1.33)

1.42 (0.97–2.08)

0.79 (0.56–1.11)

0.98 (0.92–1.05)

0.79 (0.56–1.11)

P-value

0.138

0.610

0.820

0.744

0.072

0.173

0.625

0.173

Pre-index albuminuria

HR (95 % CI)

0.76 (0.43–1.35)

1.01 (0.69–1.49)

1.25 (0.29–5.28)

1.18 (0.44–3.22)

1 (0.47–214)

1.38 (0.79–2.42)

0.91 (0.82-1)

2.08 (0.75–5.74)

P-value

0.3506

0.9418

0.7636

0.7420

0.9980

0.2630

0.0539

0.1577

Free from pre-index albuminuria

HR (95% CI)

1.01 (0.65–1.57

1.24 (0.97–1.6)

0.91 (0.2–4.07)

0.9 (0.57–1.48)

2.02 (1.09–3.76)

0.91 (0.58–1.43)

1.21 (1.05–1.4)

2.44 (1.11–5.38)

P-value

0.9716

0.0912

0.8996

0.6672

0.0261

0.6788

0.0077

0.0265

  1. Cardiorenal composite, any of eGFR < 60, micro- or macroalbuminuria and any MACE, AMI, stroke, or CVD. Renal composite, any of micro- or macroalbuminuria, eGFR 50% reduction or eGFR < 60, dialysis, renal transplantation, renal failure, renal death
  2. HRs SGLT-2 inhibitor vs. GLP-1 receptor agonist 0.78 (0.61–1.01)